Literature DB >> 35228868

Severe SARS-COV-2 infection in pediatric patient with atypical Hemolytic Uremic Syndrome: A case report.

Salih Boushra Hamza1,2.   

Abstract

INTRODUCTION AND IMPORTANT: There is a high incidence of acute kidney injury with COVID-19 infections. We report a child with atypical Hemolytic Uremic Syndrome (aHUS) admitted to Intensive care Unit (ICU) due to severe SARS-COV-2 infection. Children are recognised as at lower risk of severe COVID-19 compared with adults, but the impact of atypical Hemolytic Uremic Syndrome is yet to be determined. CASE
PRESENTATION: An eleven years old male presented to Mohammed Alamin Hamid Pediatric Hospital with generalize body swelling, skin rash and red urine. Examination reveal hepatomegaly and hemic murmur. Investigations reveal anemia, normal platelets, and impaired renal function. Peripheral blood picture shows shistocytes, crenated RBCs, occasional poikilocytes and mild neutrophilia.During hospital stay the patient developed severe shortness of breath and fever, diagnosed as COVID-19 and required ICU admission 2 days later due to severe respiratory compromised. CLINICAL DISCUSSION: An atypical Hemolytic Uremic Syndrome with normal platelets is extremely rare condition. SARS-COV-2 infection in patients atypical Hemolytic Uremic Syndrome has not been reported in literature.
CONCLUSION: Our study shown that severe SARS-COV-2 infection can be developed in pediatric patients patients with co-existing atypical Hemolytic Uremic Syndrome.
© 2022 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.

Entities:  

Keywords:  Atypical; Hemolytic uremic syndrome; Pediatric; SARS-COV-2

Year:  2022        PMID: 35228868      PMCID: PMC8867980          DOI: 10.1016/j.amsu.2022.103400

Source DB:  PubMed          Journal:  Ann Med Surg (Lond)        ISSN: 2049-0801


Introduction

Since December 2019, an outbreak of severe acute respiratory infection (SARS-COV-2) had emerged in Wuhan City, the capital of Hubei Province, China, driving an atypical pneumonia (COVID-19) [1]. A retrospective analysis showed that SARS can cause elevated serum creatinine and acute tubular necrosis, implying renal function damage in patients infected with SARS‐CoV [2]. The Hemolytic Uemic Syndrome in pediatrics is classified into two categories: typical hemolytic Uremic Syndrome with a diarrheal prodrome, and atypical Hemolytic Uremic Syndrome without diarrheal prodrome. Typical disease represent up to 90% of children with the Hemolytic Uremic Syndrome, commonly presenting before school age, with acute onset of bloody diarrhea precipitated by verotoxin-producing bacteria such as Escherichia coli O157:H7 [3]. Although many affected children have severe acute kidney injury, the majority regain effective function [4]. The classic triad of HUS is microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS presenting with normal platelet count is extremely rare [5,6]. A normal platelet count in the setting of anemia and renal failure typically leads the clinician to alternative diagnoses. This study highlights a rare case of atypical Hemolytic Uremic Syndrome that is commonly missed in real practice. To our knowledge no study highlighted the severity of SARS-COV-2 infection in pediatric patients with atypical Hemolytic Uremic Syndrome. This work has been reported in line with the SCARE 2020 criteria [7].

The case

We present eleven years old male presented to Mohammed Alamin Hamid Pediatric Hospital with generalize body swelling, skin rash and red urine. The condition started with sorethroat diagnosed initially as tonsillitis and received Amoxicillin-clavulanic acid. Then the patient received medical advice initially at primary health center and labelled to have allergic reaction manifested with papular skin rash with complete response to antihistamine. One week after that the patient developed generalize body swelling, red urine and decreased urine out-put. On examination patient was I'll, not distress, afebrile, BP was 100/70, pulse rate was 75, respiratory rate was 26, and oxygen saturation was 98%. The patient had hemic murmur and Hepatomegaly. Investigations reveal impair renal function, urine analysis show unaccountable red blood cells and granular cast (Table 1). The eGFR was 13 mL/min/1.73m2. Pt received antibiotics, amilodepine, furosomide and pulse methyl prednisolone regimen without improvement. Due to late presentation the patient was on plasma transfusion and regular hemodialysis. During hospital stay the patient developed severe shortness of breath and fever. PCR for SARS-COV-2 infection was positive. Patient received Paracetamol 500mg, Aspirin 100 mg, Vitamin D, Dexamethasone 6 mg according to protocol developed by Case Management Committee, Federal Ministry of Health, Sudan [1]. Patient's oxygen saturation maintained with high follow through face mask. Two days later the patient was admitted to ICU due to severe respiratory compromise.
Table 1

Initial investigations.

InvestigationResult
Hemoglobin6.8 g/dl
MCV75 fL
MCH24.3 pg
MCHC30 g/dl
Platelets267 × 10³/μl
TWBCs9.8 × 10³/μl
Retics5.5%
ESR75 mm/1 hr
Urea107 mg/dl
Creatinine6.3 mg/dl
Sodium133 mmol/l
Potassium3.3 mmol/l
Serum albumin5.6 g/dl
Total bilirubin7.6 mg/dl
Direct bilirubin6.4 mg/dl
Total proteins7.6 g/dl
Globulins2 g/dl
ALP96 IU/L
AST54 IU/L
ALT27 IU/L
PT21 sec
PTT55 sec
INR1.42
CRP18.5 mg/dl
ASO titerless than 200
Urine RBCsuncountable
Urine pus cellsUncountable
Urine granular casts++
Urine protein++
Peripheral blood pictureShistocytes, crenated RBCs, occasional poikilocytes and mild neutrophilia
C3 level32 mg/dl
C4 level28 mg/dl
Initial investigations.

Discussion

We describe a case of 11 years old with features of atypical Hemolytic uremic syndrome infected with COVID-19. Atypical hemolytic–uremic syndrome occurs at any age, and the onset tends to be insidious, often with marked hypertension; relapses occur that lead ultimately to end-stage renal disease [4]. Unlike typical HUS there is no specific prodromal diarrheal illness, although atypical Hemolytic Uremic Syndrome may occur after or simultaneously with illness, and severe pneumococcal disease associated with 30–40% of pediatric cases [8]. Absence of diarrheal prodrome is essential to differentiate between typical and atypical HUS. Some types of Streptococcus pneumoniae produce a neuraminidase that cleaves sialic acid residues from renal endothelial cells, thereby exposing the Thomsen–Friedenreich (T) antigen to an anti-T immunoglobulin commonly found in the plasma, leading to endothelial damage and thrombotic microangiopathy [9]. COVID-19 is also associated with a pro-thrombotic state with increased risk of thrombosis and disseminated intravascular coagulation (DIC) [10,11]. Our search report a cases of COVID-19 in HUS patients in both adult and children. Ville et al. reported a case of atypical HUS relapse in a 28-year-old woman who was positive for COVID-19 [12]. Another study report a 16-month-old boy, presented with COVID-19, new onset DKA, hemolytic anemia, thrombo-cytopenia and kidney failure. He was given a trial of fresh frozen plasma, however there was no improvement [13]. It has been reported in the past that trombotic micro-angiopathy/atypical HUS can relapse in the setting of viral illnesses like infuenza. Some authors have suggested adding COVID-19 as a triggering factor for a HUS relapse.

Conclusion

We presented a case severe SARS-COV-2 infection in a child with atypical Hemolytic Uremic Syndrome with normal platelets and absence of diarrheal prodrome.

Data sharing statement

The datasets referred to in this case report are available from the corresponding author on reasonable request.

Ethical approval

N/A.

Sources of funding

N/A.

Author contribution

The corresponding author made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

Conflicts of interest

We declare no conflict of interests.

Provenance and peer review

Not commissioned, externally peer reviewed.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. Patient's parents have given consent for possible publication of this case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Research registration

N/A.

Guarantor

The corresponding author, Salih Boushra Hamza is the Guarantor for this manuscript.
  12 in total

Review 1.  Haemolytic uraemic syndrome: an overview.

Authors:  Iradj Amirlak; Bardia Amirlak
Journal:  Nephrology (Carlton)       Date:  2006-06       Impact factor: 2.506

2.  The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines.

Authors:  Riaz A Agha; Thomas Franchi; Catrin Sohrabi; Ginimol Mathew; Ahmed Kerwan
Journal:  Int J Surg       Date:  2020-11-09       Impact factor: 6.071

3.  Toddler With New Onset Diabetes and Atypical Hemolytic-Uremic Syndrome in the Setting of COVID-19.

Authors:  Faraz Alizadeh; Amanda O'Halloran; Areej Alghamdi; Charlotte Chen; Maria Trissal; Avram Traum; Danielle DeCourcey
Journal:  Pediatrics       Date:  2020-10-09       Impact factor: 7.124

4.  A clinico-pathologic study of crescentic glomerulonephritis in 50 children. A report of the Southwest Pediatric Nephrology Study Group.

Authors: 
Journal:  Kidney Int       Date:  1985-02       Impact factor: 10.612

Review 5.  Hemolytic uremic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2005-02-23       Impact factor: 10.121

6.  Acute renal failure in SARS patients: more than rhabdomyolysis.

Authors:  Vin-Cent Wu; Po-Ren Hsueh; Wei-Chou Lin; Jenq-Wen Huang; Hung-Bin Tsai; Yung-Ming Chen; Kwan-Dun Wu
Journal:  Nephrol Dial Transplant       Date:  2004-12       Impact factor: 5.992

7.  High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.

Authors:  Julie Helms; Charles Tacquard; François Severac; Ian Leonard-Lorant; Mickaël Ohana; Xavier Delabranche; Hamid Merdji; Raphaël Clere-Jehl; Malika Schenck; Florence Fagot Gandet; Samira Fafi-Kremer; Vincent Castelain; Francis Schneider; Lélia Grunebaum; Eduardo Anglés-Cano; Laurent Sattler; Paul-Michel Mertes; Ferhat Meziani
Journal:  Intensive Care Med       Date:  2020-05-04       Impact factor: 17.440

8.  Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis.

Authors:  Wei-Jie Guan; Wen-Hua Liang; Yi Zhao; Heng-Rui Liang; Zi-Sheng Chen; Yi-Min Li; Xiao-Qing Liu; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Chun-Quan Ou; Li Li; Ping-Yan Chen; Ling Sang; Wei Wang; Jian-Fu Li; Cai-Chen Li; Li-Min Ou; Bo Cheng; Shan Xiong; Zheng-Yi Ni; Jie Xiang; Yu Hu; Lei Liu; Hong Shan; Chun-Liang Lei; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Lin-Ling Cheng; Feng Ye; Shi-Yue Li; Jin-Ping Zheng; Nuo-Fu Zhang; Nan-Shan Zhong; Jian-Xing He
Journal:  Eur Respir J       Date:  2020-05-14       Impact factor: 16.671

9.  Successful treatment of a COVID-19 patient with thrombotic microangiopathy.

Authors:  Seda Safak; Elif Aksoy; Ahmet Burak Dirim; Erol Demir; Nurana Garayeva; Ozgur Akin Oto; Ayse Serra Artan; Halil Yazici; Sevgi Besisik; Aydin Turkmen
Journal:  Clin Kidney J       Date:  2021-01-29

10.  COVID-19 and its implications for thrombosis and anticoagulation.

Authors:  Jean M Connors; Jerrold H Levy
Journal:  Blood       Date:  2020-06-04       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.